. . . . . . . . . . . . . . "Investigated for use/treatment in nocturia (frequent nighttime urination) and urinary incontinence."@en . . . . . . . . . . . . . "# Nakamura S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Yamamura Y, Mori T, Tominaga M: Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats. J Pharmacol Exp Ther. 2000 Dec;295(3):1005-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11082435"@en . . . "OPC-51803"@en . "OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence."@en . "investigational"@en . . . . .